Astellas, Aveo End Collaboration On Developing Tivozanib As Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma and U.S.-based Aveo Oncology are dropping their collaboration on developing tivozanib as a treatment for breast and colon cancers because of poor results in a Phase II trial.